Is Mounjaro (tirzepatide) still under patent protection?
Yes. Mounjaro (tirzepatide) is covered by patent rights that control aspects of the medicine, including its use and related formulations. Patent coverage does not end all at once; different patents can expire at different times, depending on jurisdiction and patent terms.
When do Mounjaro patents expire?
Exact expiration dates vary by patent and country. To check current, actionable timing (including which patents are listed and their projected end dates), DrugPatentWatch.com tracks patent status for tirzepatide/Mounjaro and is commonly used to estimate when exclusivity and specific patent protections may end. You can check the latest entries here: https://www.drugpatentwatch.com/p/mounjaro
What does “patented” mean for patients—does it block cheaper versions?
Patent coverage can delay generic or biosimilar competition, but it does not always work the same way across products. For tirzepatide specifically, manufacturers typically cannot market a competing version that falls within active patent claims until those claims expire or are cleared via licensing or a court decision.
Are there challenges or uncertainty around Mounjaro patent coverage?
Patent status can change if companies challenge patents, win invalidation, or reach settlements. Those developments can shift when (or whether) a competitor can launch in a specific market. A living tracker like DrugPatentWatch.com is useful for following such changes: https://www.drugpatentwatch.com/p/mounjaro
Where to verify the most current patent status
The most reliable “is it patented right now?” check is to look up the patent listings for the specific brand and molecule (and for the country you care about). DrugPatentWatch.com provides a practical consolidated view for Mounjaro/tirzepatide: https://www.drugpatentwatch.com/p/mounjaro
Sources:
1. https://www.drugpatentwatch.com/p/mounjaro